DRUG DISCOVERY FOR VCs: HOW TO DE-RISK YOUR INVESTMENT

Drug discovery for VCs: How to de-risk your investment

With Carmen Diez Fernandez & Arnoud Huisman & Dr. Charlotte Kopitz

The notorious high attrition rate in the discovery phase often curbs the early-stage venture capital enthusiasm. To increase your chances of scientific success, our approach is to gain a very early in-depth understanding of your molecule as well as of the patient population which most likely benefits from treatment. We, the science CRO Nuvisan, are ready to have skin in the game at your side by helping to grow the value of your portfolio and your ROI.